ABSTRACT
Objective@#To explore the effect and safety of two chemotherapy regimens in the treatment of small cell lung cancer.@*Methods@#Ninety-eight patients with extensive small cell lung cancer admitted to Liuzhou People′s Hospital of Guangxi Zhuang Autonomous Region from March 2013 to March 2016 were randomly divided into two groups by random number table method, 49 of whom were treated with lobaplatin + etoposide (EL group), and another 49 cases were treated with cisplatin + etoposide (EP group). The short-term efficacy, 2-year survival rate and adverse reactions of the two groups were observed. The serum levels of gastrin-releasing peptide precursor (ProGRP), neuron-specific enolase (NSE), Ki-67, vascular endothelial growth factor (VEGF) were compared between the two groups before and after treatment.@*Results@#The effective rates of the EL group and the EP group were 48.98% (24/49) and 40.82%(20/49) respectively, and the difference between the two groups was not statistically significant (χ2=0.660, P=0.417). The 2-year survival rates of patients in the EL group and the EP group were 17.07% and 11.11% respectively. The median survival time of the EL group was 17.00 months, and that of the EP group was 15.00 months. There was no significant difference between the two groups (χ2=1.094, P=0.228). The serum level of ProGRP was (978.4±225.7) ng/L and (940.2±237.1) ng/L, NSE was (43.9±10.3) ng/ml and (41.7±11.6) ng/ml, Ki-67 was (287.5±55.3) pg/ml and (279.8±62.6) pg/ml, and VEGF was (566.8±109.4) pg/ml and (538.1±144.0) pg/ml in the EL and EP group before chemotherapy respectively, and there were no significant differences between the two groups (t=0.817, P=0.416; t=0.993, P=0.323; t=0.645, P=0.520; t=1.111, P=0.269). The serum level of ProGRP was (167.3±68.5) ng/L and (180.6±62.1) ng/L, NSE was (17.5±4.8) ng/ml, (19.0±5.3) ng/ml, Ki-67 was (98.0±18.6) pg/ml and (101.4±20.8) pg/ml, VEGF was (430.4±95.8) pg/ml and (442.8±91.0) pg/ml in the EL and EP group after chemotherapy, and there was no significant difference between the two groups (t=-1.007, P=0.316; t=-1.468, P=0.145; t=-0.853, P=0.396; t=-0.657, P=0.513). The serum levels of ProGRP, NSE, Ki-67 and VEGF in EL group and EP group were significantly lower than those before chemotherapy (t=24.072, P<0.001; t=21.694, P<0.001; t=16.263, P<0.001; t=12.459, P<0.001; t=22.736, P<0.001; t=18.931, P<0.001; t=6.566, P<0.001; t=3.916, P<0.001). During chemotherapy, the incidences of diarrhea and myelosuppression (≥grade 2) in the EL group [26.53% (13/49) and 61.22% (30/49)] were lower than those in the EP group [48.98% (24/49) and 81.63% (40/49)], and the differences were statistically significant (χ2=5.254, P=0.022; χ2=5.000, P=0.025).@*Conclusion@#Lobaplatin+ etoposide is less toxic than cisplatin+ etoposide in the treatment of small cell lung cancer, and adverse reactions of its is relatively slighter.
ABSTRACT
Objective To explore the effect and safety of two chemotherapy regimens in the treatment of small cell lung cancer. Methods Ninety-eight patients with extensive small cell lung cancer admitted to Liuzhou People's Hospital of Guangxi Zhuang Autonomous Region from March 2013 to March 2016 were ran-domly divided into two groups by random number table method,49 of whom were treated with lobaplatin + eto-poside (EL group),and another 49 cases were treated with cisplatin + etoposide (EP group). The short-term efficacy,2-year survival rate and adverse reactions of the two groups were observed. The serum levels of gas-trin-releasing peptide precursor (ProGRP),neuron-specific enolase (NSE),Ki-67,vascular endothelial growth factor (VEGF)were compared between the two groups before and after treatment. Results The effec-tive rates of the EL group and the EP group were 48. 98％ (24 / 49)and 40. 82％(20 / 49)respectively,and the difference between the two groups was not statistically significant (χ2 = 0. 660,P = 0. 417). The 2-year sur-vival rates of patients in the EL group and the EP group were 17. 07％ and 11. 11％ respectively. The median survival time of the EL group was 17. 00 months,and that of the EP group was 15. 00 months. There was no significant difference between the two groups (χ2 = 1. 094,P = 0. 228). The serum level of ProGRP was (978. 4 ± 225. 7)ng/ L and (940. 2 ±237. 1)ng/ L,NSE was (43. 9 ±10. 3)ng/ ml and (41. 7 ±11. 6)ng/ ml, Ki-67 was (287. 5 ± 55. 3)pg/ ml and (279. 8 ± 62. 6)pg/ ml,and VEGF was (566. 8 ± 109. 4)pg/ ml and (538. 1 ±144. 0)pg/ ml in the EL and EP group before chemotherapy respectively,and there were no significant differences between the two groups (t = 0. 817,P = 0. 416;t = 0. 993,P = 0. 323;t = 0. 645,P = 0. 520;t =1. 111,P = 0. 269). The serum level of ProGRP was (167. 3 ± 68. 5)ng/ L and (180. 6 ± 62. 1)ng/ L,NSE was (17. 5 ±4. 8)ng/ ml,(19. 0 ±5. 3)ng/ ml,Ki-67 was (98. 0 ± 18. 6)pg/ ml and (101. 4 ± 20. 8)pg/ ml, VEGF was (430. 4 ±95. 8)pg/ ml and (442. 8 ±91. 0)pg/ ml in the EL and EP group after chemotherapy,and there was no significant difference between the two groups (t = - 1. 007,P = 0. 316;t = - 1. 468,P = 0. 145;t = - 0. 853,P = 0. 396;t = - 0. 657,P = 0. 513). The serum levels of ProGRP,NSE,Ki-67 and VEGF in EL group and EP group were significantly lower than those before chemotherapy (t = 24. 072,P < 0. 001;t =21. 694,P < 0. 001;t = 16. 263,P < 0. 001;t = 12. 459,P < 0. 001;t = 22. 736,P < 0. 001;t = 18. 931, P < 0. 001;t = 6. 566,P < 0. 001;t = 3. 916,P < 0. 001). During chemotherapy,the incidences of diarrhea and myelosuppression (≥grade 2)in the EL group [26. 53％ (13 / 49)and 61. 22％ (30 / 49)]were lower than those in the EP group [48. 98％ (24 / 49)and 81. 63％ (40 / 49)],and the differences were statistically significant (χ2 = 5. 254,P = 0. 022;χ2 = 5. 000,P = 0. 025). Conclusion Lobaplatin + etoposide is less toxic than cisplatin +etoposide in the treatment of small cell lung cancer,and adverse reactions of its is relatively slighter.
ABSTRACT
Objective :To explore therapeutic effect of percutaneous coronary intervention (PCI ) combined hydro‐chloride tirofiban on aged patients with acute coronary syndrome (ACS) complicated diabetes mellitus (DM) and its safety .Methods :A total of 218 ACS + DM patients were selected .According to randomization method ,they were divided into routine treatment group (n＝107 ,received standard PCI) and tirofiban group (n＝111 ,received tirofi‐ban injection in coronary artery based on routine treatment group ).Operation indexes ,incidence rates of hemor‐rhage during hospitalization and major adverse cardiovascular events (MACE) within six months after PCI were ob‐served and compared between two groups .Results : There was no significant difference in door‐to‐balloon time , number and length of implanted stents between two groups , P＞0.05 all.Compared with routine treatment group , there were significant rise in percentages of TIMI grade 3 blood flow (75. 70% vs.91.89%) ,MBG grade 2 ～3 (69.16% vs.85.56%) and ST segment regression ＞50% within 90min after PCI (77. 57% vs.92.79%) ,and sig‐nificant reduction in corrected TIMI frame count (CTFC)[(33. 05 ± 8.37) frames vs.(26.54 ± 5.47) frames]in tiro‐fiban group , P＜0.01 all.There was no significant difference in incidence rate of hemorrhage events during hospi‐talization between two groups , P＝0.375. Incidence rate of MACE within six months in tirofiban group was signifi‐cantly lower than that of routine treatment group ,P＝0.001 .Conclusion :Intracoronary tirofiban injection based on routine PCI can significantly improve postoperative myocardial perfusion level ,reduce incidence rate of short‐term MACE after PCI without increasing incidence rate of hemorrhage in aged ACS patients .Its safety is good .
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the changes in human airway smooth muscle cell (HASMC) migration and related signaling pathway after interference with PTEN gene expression.</p><p><b>METHOD</b>HASMCs were infected with an adenovirus vector and RNA interference vector of human PTEN gene to establish the cell model with PTEN gene over-expression (Ad-GFP-PTEN-HASMC) and one with PTEN gene silencing (Ad-shPTEN-HASMC), using Ad-GFP-infected and a blank cells as the negative controls and LY294002 as the positive control. Fluorescence microscopy and flow cytometric analysis were used to evaluate the transfection efficiency, and Western blotting was performed to examine the expression of PTEN and the activation of AKT and ERK1/2 signal pathway. Transwell assay and wound healing assay were used to assess the migration of HASMCs.</p><p><b>RESULTS</b>The adenovirus over-expression vector and RNA interference vector significantly affected the expression of human PTEN gene. Up-regulation of PTEN gene resulted in a slow-down of the HASMC migration, an inhibition of PI3K/AKT signal pathway at the protein level but no changes in Ras-Raf-MEK1/2-ERK1/2 signal pathway. Down-regulated PTEN gene expression, however, was not associated with an enhancement of HASMC migration, but activated PI3K/AKT signal pathway and inhibited Ras-Raf-MEK1/2-ERK1/2 signal pathway.</p><p><b>CONCLUSION</b>Upregulation of PTEN gene can effectively inhibit airway smooth muscle cell migration, the effect of which is probably mediated by the PI3K/AKT pathway.</p>